Silexion Therapeutics (NASDAQ:SLXN) Posts Quarterly Earnings Results, Beats Expectations By $20.49 EPS

Posted by James Conley on Mar 17th, 2026

Silexion Therapeutics (NASDAQ:SLXN – Get Free Report) issued its quarterly earnings data on Tuesday. The company reported $19.32 EPS for the quarter, beating analysts’ consensus estimates of ($1.17) by $20.49, FiscalAI reports.

Silexion Therapeutics Stock Performance

NASDAQ SLXN traded down $0.01 during trading on Tuesday, hitting $1.56. The company’s stock had a trading volume of 6,230 shares, compared to its average volume of 36,404. Silexion Therapeutics has a 52 week low of $1.42 and a 52 week high of $22.36. The firm has a market cap of $4.88 million, a P/E ratio of -0.14 and a beta of -0.04. The firm has a 50 day moving average price of $1.84 and a 200 day moving average price of $2.87. The company has a quick ratio of 3.97, a current ratio of 3.97 and a debt-to-equity ratio of 0.22.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on SLXN. Zacks Research raised Silexion Therapeutics to a “hold” rating in a research report on Tuesday, December 16th. Wall Street Zen lowered shares of Silexion Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, December 20th. Finally, Litchfield Hills Research began coverage on shares of Silexion Therapeutics in a report on Monday, December 15th. They set a “buy” rating for the company. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Silexion Therapeutics presently has an average rating of “Hold” and a consensus price target of $75.00.

Read Our Latest Research Report on Silexion Therapeutics

About Silexion Therapeutics

(Get Free Report)

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.